Open access peer-reviewed Edited Volume

Drug Design - Novel Advances in the Omics Field and Applications

Arli Aditya Parikesit

Indonesia International Institute for Life Sciences


Metabolomics Structural Biology Advances Transcriptomics Next-Generation-Sequencing Molecular Structure Elucidation Epigenomics Instrumentation Proteomics Genomics Annotations Gene Prediction

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

The advancements of omics fields have enabled various possibilities in drug design enhancements. One of the most significant advances would be the inception of bioinformatics as an independent branch of science that facilitated the deposition of omics data in massive scale or big data, namely with the assistance of the data science-based infrastructure, that would be beneficial for drug design advancement. The advancement in bioinformatics did not evolve independently from the wet laboratory improvement. The field of structural biology and metabolomics has enabled fine-grained biomolecules structural elucidation with X-ray diffraction, NMR, and Cryo-EM sophisticated methods within the assistance of the conventional biochemistry instrumentation such as LC-MS, HPLC, and GC. Moreover, transcriptomics research has enabled the next-generation-sequencing instrument to annotate genomes on a massive scale.

The novel advancement of the epigenomics study also opens the horizon of drug design methods into a massive influx of histone marks information. These aforementioned approaches in omics studies have eventually enriched the existing established ones of proteomics and genomics. As the deposited data is very complex, it is necessary for the bioinformaticians and wet laboratory practicians to collaborate in order to resolve the increasing challenges in drug design. There are drug design challenges in infectious disease that should be resolved; not to mention the problems of ‘civilization diseases’ such as cancer, Alzheimer, cardiovascular, type 2 diabetes, obesity, and others.

In this end, as drug design is becoming more and more multi-disciplinary, it is necessary to ward off the ego-sectoral approach that has fragmented the scientific community as a way to leverage innovation in this field.

Publishing process

Book initiated and editor appointed

Date completed: May 18th 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: June 8th 2020

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: August 7th 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 26th 2020

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 25th 2020

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Arli Aditya Parikesit

Indonesia International Institute for Life Sciences

Dr Arli Aditya Parikesit is the Head of the Bioinformatics Department at i3L. He finished his bachelor and master degrees, both in Chemistry, from the University of Indonesia. In order to pursue his degree in Bioinformatics, he accepted a DAAD (German Academic Exchange Service) fellowship to conduct his doctorate research with the Bioinformatics Group, Faculty of Informatics and Mathematics, University of Leipzig, Germany. His doctoral research is focused on the utilization of modern protein domain annotation techniques to the three domains of life. In addition, Dr Arli is also an expert on immunoinformatics, in silico drug design, and in silico transcriptomics.

View profile

Book chapters authored 2

Books edited 1

Introducing your Author Service Manager

Mr. Edi Lipovic

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in